title: Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer.
abstract: OBJECTIVE
  The aim of this study was to evaluate the therapeutic efficacy and safety of trastuzumab emtansine (T-DM1) for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer.
  
  
  METHODS
  We performed a systemic review and meta-analysis of the relevant published clinical studies. A computerized search was performed for controlled clinical trials of T-DM1 in targeted treatment. Overall survival, progression-free survival, objective response rate, symptom progression free, and adverse events (AEs) were evaluated.
  
  
  RESULTS
  Eight eligible trials with a total of 2,016 patients with breast cancer were included in the present meta-analysis. The treatment of patients with breast cancer with T-DM1 was associated with significantly increased overall and progression-free survival when compared with controls (P<0.0001). An analysis of the objective response rate and symptom progression free also demonstrated favorable results for T-DM1 treatment (P≤0.0001). There was no significant difference between the T-DM1 and control groups with respect to nonhematologic or hematologic AEs (P=0.99 and P=0.30, respectively).
  
  
  CONCLUSIONS
  Overall, T-DM1 is efficacious in the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer and low rates of AEs compared with controls.
authors.affiliation: Affiliated Central Hospital of Huzhou Teachers College, Huzhou, Zhejiang, People's Republic of China.
authors.forename: Bo
authors.initials: B
authors.lastname: Ma
authors.affiliation: University Hospital of Tuebingen, Tuebingen, Germany.
authors.forename: Qianqian
authors.initials: Q
authors.lastname: Ma
authors.affiliation: Department of Oncology, Hospital of Zhoushan, Zhoushan, Zhejiang, People's Republic of China.
authors.forename: Hongqiang
authors.initials: H
authors.lastname: Wang
authors.affiliation: Affiliated Central Hospital of Huzhou Teachers College, Huzhou, Zhejiang, People's Republic of China.
authors.forename: Guolei
authors.initials: G
authors.lastname: Zhang
authors.affiliation: Affiliated Central Hospital of Huzhou Teachers College, Huzhou, Zhejiang, People's Republic of China.
authors.forename: Huiying
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Affiliated Central Hospital of Huzhou Teachers College, Huzhou, Zhejiang, People's Republic of China.
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Wang
keywords: HER2; T-DM1; breast cancer; efficacy; meta-analysis